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ABSTRACT
The present study was planned to investigate the action of pregabalin on voltage-dependent Ca 2+ channels (VDCC) and on novel targets (fusion pore formed between the secretory vesicle and the plasma membrane, exocytotic machinery and mitochondria) that would further explain its inhibitory action on neurotransmitter release. Electrophysiological recordings in the perforated-patch configuration of the patch-clamp technique revealed that pregabalin inhibits by 33.4±2.4% and 39±4%, respectively, the Ca 2+ current charge density and exocytosis evoked by depolarizing pulses in mouse chromaffin cells. About half of the inhibitory action of pregabalin was rescued by Lisoleucine, showing the involvement of α2δ-dependent and  independent mechanisms. Ca 2+ channel blockers were used to inhibit Cav1.2, Cav2.1 and Cav2.2 channels in mouse chromaffin cells, which were unselectively blocked by the drug. Similar values of Ca 2+ current charge blockade were obtained when pregabalin was tested in human or bovine chromaffin cells, species that express very different percentage of VDCC types with respect to mouse chromaffin cells. These results demonstrate that the inhibitory action of pregabalin on VDCC and exocytosis does not depend on α1 Ca 2+ channel subunit types. Carbon fibre amperometric recordings of digitonin-permeabilized cells showed that neither the fusion pore nor the exocytotic machinery were targeted by pregabalin.
Mitochondrial Ca 2+ measurements performed with mit-r-Pericam demonstrated that Ca 2+ uptake or release from mitochondria were not either affected by the drug. The selectivity of action of pregabalin might explain its safety, good tolerability and reduced adverse effects. In addition, the inhibition of the exocytotic process in chromaffin cells might have relevant clinical consequences.
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INTRODUCTION
PBG ((S)-3-(aminomethyl)-5-methylhexanoic acid) is a drug indicated in the treatment of central
and peripheral neuropathic pain and generalized anxiety disorder, and in the adjunctive therapy of partial seizures in adults. Its mechanism of action has not been completely clarified. The inhibitory effect of pregabalin on voltage dependent Ca 2+ channels (VDCC) after acute application of the drug has been reported (Dooley et al., 2002; Fink et al., 2002; McClelland et al., 2004) . Pregabalin preferentially blocks Cav2.1 channels in rat neocortical slices (Dooley et al., 2002) , human neocortical synaptosomes (Fink et al., 2002) or mice neurons of the calyx of Held (Di Guilmi et al., 2011 ).
In addition, many studies have documented the effect of pregabalin on neurotransmitter release.
Pregabalin inhibits the release of glutamate in rat entorhinal synapses in vitro (Cunningham et al., 2004) and in rat neocortical and hippocampal slices (Dooley et al., 2000a) , noradrenaline (Dooley et al, 2000b) , acetylcholine and serotonine (Dooley et al., 2000a , 2000b : Brawek et al., 2008 in human and rat neocortical slices, glutamate in rodent neocortical slices (Quintero et al., 2011) , GABA in human neocortical synaptosomes (Brawek et al., 2009 ) and capsaicin-evoked substance P and calcitonin gene-related peptide in rat spinal cord slices (Fehrenbacher et al., 2003) . Pregabalin is a potent and selective ligand for α2δ-1 and α2δ-2 Ca 2+ channel subunits (Li et al., 2011) . Indeed, α2δ-1 subunits of VDCC have been identified as the molecular target for the analgesic action exerted by pregabalin (Field et al., 2006) , as well as for its inhibitory effect on glutamate release in rodent neocortical slices (Quintero et al., 2011) . Besides the action of pregabalin on α2δ subunits to inhibit release (Micheva et al., 2006; Joshi et al., 2006; Quintero et al., 2011) , it has been postulated that an independent mechanism to Ca 2+ entry through VDCC might be involved (Cunningham et al., 2004; McClelland et al., 2004; Micheva et al., 2006) . This article has not been copyedited and formatted. The final version may differ from this version.
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In fact, pregabalin uses the system L of amino acid transport across the plasma membrane to access the cytosol (Jezyk et al., 1999; Su et al., 2005) , where it might be acting on different targets to generate its neuronal effects. In this sense, pregabalin could reach the axoplasm, act on the exocytotic machinery that controls neurotransmitter release or accumulate into intracellular organelles such as mitochondria. Indeed, antiepileptic drugs such as topiramate have shown to affect the SNARE-associated monoamine exocytotic mechanism (Okada et al., 2005) . In addition, there has been increasing evidence supporting the association between mitochondrial oxidative stress and epilepsy (Waldbaum and Patel, 2010a, b; Folbergrová and Kunz, 2011) . Several mutations in the electron transport chain associated with epilepsy have been described (Shoffner et al., 1990; TryoenTóth et al., 2003; Kudin et al., 2009) . Given that mitochondria can reach Ca 2+ transients of millimolar concentration (Montero et al., 2000) , the consequence of those mutations would be the inefficiency to buffer Ca
2+
, and therefore, the uncontrolled elevation of cytosolic Ca
This increment in the cytosolic Ca 2+ concentration will enhance neurotransmitter release, triggering epileptogenic action potentials at the postsynaptic level.
The goal of the present study was to further investigate the effect of pregabalin on VDCC, and also on additional targets such as the fusion pore formed between the plasma membrane and the secretory vesicle, the exocytotic apparatus or the mitochondria. To this purpose, we used chromaffin cells of the adrenal gland, modified postganglionic sympathetic neurons innervated by the splanchnic nerve that mainly control the release of adrenaline to the bloodstream, in order to prepare muscle and cardiovascular systems to a situation of stress. Our study shows that pregabalin unselectively inhibited Cav1, Cav2.1 and Cav2.2 channels. This inhibitory effect was halved by Lisoleucine (ILE), which binds to the α2δ-auxiliary subunit of VDCC. Furthermore, similar percentages of blockade were exerted by pregabalin on the VDCC of chromaffin cells from mice, human and bovine species, which express very different percentages of VDCC types. This means This article has not been copyedited and formatted. The final version may differ from this version. channels, but most probably on their α2δ auxiliary subunits. In addition, no intracellular effects on the fusion pore, the exocytotic machinery or the mitochondria were here observed, which might explain the selectivity of action of this drug, its reduced adverse effects respect to other antiepileptic drugs, as well as its safety and tolerability.
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MATERIAL AND METHODS
Isolation and culture of mouse, human and bovine chromaffin cells
Mice from 2 to 3 months old were used to obtain the adrenal glands. The procedure of isolation and culture of cells was performed as previously reported (Pérez-Alvarez et al., 2011) . The study protocol for the use of human chromaffin cells was approved by the Ethics Committees of the Hospital Ramón y Cajal and Universidad Autónoma de Madrid. Adrenal glands were harvested from two organ donors who had died of cerebral hemorrhage. The method of isolation and culture of the human chromaffin cells was performed as previously reported (Pérez-Alvarez et al., 2007) .
Bovine chromaffin cells from adrenal glands of adult cows were isolated according to the method reported by Moro and coworkers (1990) .
Electrophysiological recordings
For the perforated-patch whole-cell recordings, the external solution was (in mM): 5 CaCl 2 , 100
NaCl, 45 TEACl, 5.5 KCl, 1 MgCl 2 , 0.2 d-tubocurarine, 0.002 TTX, 0.0002 apamin, 10 HEPES and 10 glucose (pH 7.4 adjusted with NaOH). The intracellular solution composition was (in mM): 145
Cs-glutamate, 8 NaCl, 1 MgCl 2 , 10 HEPES and 0.5 amphotericin B (Sigma-Aldrich, Madrid, Spain) and the pH was adjusted to 7.2 with CsOH. An amphotericin B stock solution was prepared every day at a concentration of 50 mg/mL in dimethyl sulphoxide (DMSO) and kept protected from light. The final concentration of amphotericin B was prepared by ultrasonicating 10 µL of stock amphotericin B in 1 mL of Cs-glutamate internal solution in the dark. Pipettes were tip-dipped in amphotericin-free solution for several seconds and back-filled with freshly mixed intracellular amphotericin solution.
The perfusion system for drug application consisted of a multi-barrelled glass pipette positioned close to the cell under study, which allowed the complete exchange of solutions near the cell within of the "PULSE" lock-in software. A 1 kHz, 70 mV peak-to-peak amplitude sinewave was applied at a holding potential (V h ) of -80 mV.
All toxins used to pharmacologically characterize the Ca 2+ channels were purchased from Peptide Institute Inc., Osaka, Japan, except the dihidropyridine nifedipine which was purchased from Sigma. Pregabalin was always perfused for at least 15 min in every experiment.
Experiments were performed at room temperature (22-24ºC). Analysis of data was conducted using IGOR Pro software (Wavemetrics, Lake Oswego, Oregon). The nonspecific background current and C m recorded under 200 μ M CdCl 2 were subtracted off-line from Ca 2+ current and C m traces.
Unless otherwise stated, data are given as the mean±S.E.M. Data were compared using paired or unpaired Student's t-test.
Amperometric recordings
Carbon fiber electrodes were prepared by cannulating a 10 µm-diameter carbon fiber in polyethylene tubing (diameter: outer, 1 mm; inner, 0.5 mm). The carbon fiber tip was glued into a This article has not been copyedited and formatted. The final version may differ from this version. 
Analysis of amperometric data
Spike analysis was performed using IGOR Pro software and macros that allow the analysis of single events and the rejection of overlapping spikes (Segura et al. 2000; Mosharov and Sulzer, 2005 Lim et al., 1996) and titering of the amplicon with a titer of 1,02 x 10 7 infectious vector units (ivu) x ml -1 was performed as previously described (Chamero et al., 2008) . 5 μ l of the virus suspension was added to each well containing 600 μ l of DMEM. After gentle shaking, the plate was introduced into the culture chamber for 90 min, and later on 1 ml DMEM was added to each well. Experiments were performed 12-24 hrs after this procedure.
Cells expressing mit-r-pericam were placed in the perfusion chamber in standard medium containing 145 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 10 mM glucose, and 10 mM HEPES, pH 7.4. Standard medium containing 0.5 mM EGTA instead of CaCl 2 was then perfused for 1 min, followed by a 1-min perfusion of intracellular medium ( 
RESULTS
Pregabalin inhibits VDCC and exocytosis in mouse chromaffin cells
To investigate The inhibition of pregabalin on VDCC is mediated by α2δ auxiliary subunits in mouse chromaffin cells
Next experiments were conducted to investigate whether the observed inhibitory effect of pregabalin on VDCC in mouse chromaffin cells was exerted through its interaction with α 2δ
subunits, as reported in other cell systems (Thurlow et al., 1993; Cunningham et al., 2004; Micheva et al., 2006; Joshi et al., 2006; Quintero et al., 2011) . To achieve that purpose, L-isoleucine (ILE), which binds to the α 2δ subunit of VDCC (Brown et al., 1998; Dooley et al. 2007; Brawek et al., 2009 ), was tested. The time course of Ca 2+ charge blockade and the original recordings of the Ca 2+ currents after perfusion of ILE or ILE in the presence of pregabalin are shown in Fig. 2A and 1 µM ω -conotoxin GVIA (ω-Ctx GVIA) were used to block Cav1, Cav2.1 and Cav2.2 channels, respectively. The action of pregabalin on Cav2.3 channels could not be investigated, since SNX-482, the selective Ca 2+ channel blocker available to inhibit Cav2.3 channels, also inhibit Cav2.1 channels in chromaffin cells (Arroyo et al., 2003) .
This article has not been copyedited and formatted. The final version may differ from this version. (Albillos et al., 1993; Albillos et al., 1996; García-Palomero et al., 2000) .
The time course of Ca 2+ charge blockade exerted by 30 μ M pregabalin and the original traces of the Ca 2+ currents under control and pregabalin conditions in human and bovine chromaffin cells are
shown Fig. 4A and B, respectively. The blockades of the Ca 2+ charge density obtained were similar to those achieved in mouse, amounting to 33.6±7% and 32.6±4%, respectively, in human (n=7) and bovine (n=9) chromaffin cells. Also, the exocytotic process was blocked at a similar extent in human (36.7±12.5%, n=7) and bovine (40±7%, n=6) chromaffin cells. These data suggest that the inhibitory action of pregabalin on VDCC does not either depend on α 1 Ca 2+ channel types, as previously reported for gabapentin in DRG neurons.
Pregabalin does not act on the fusion pore or the exocytotic machinery in mouse chromaffin cells
Carbon fibre amperometric recordings were performed to assess the action of pregabalin on the fusion pore or the intracellular exocytotic machinery. Chromaffin cells possess all the same elements that build the secretory apparatus in neurons (Neher 1998) and the released catecholamines can be detected at the single level using the carbon fibre amperometric technique (Wightman et al., 1991) . Each vesicle that exhibits exocytosis generates a spike with kinetic properties that can be determined. The release of neurotransmitter molecules through the narrow fusion pore formed after the fusion of a chromaffin vesicle with the plasma membrane appears as a This article has not been copyedited and formatted. The final version may differ from this version. "foot" signal that precedes the main body of the amperometric spikes (Chow et al., 1992; Albillos et al., 1997) . If pregabalin interacts with some element of the exocytotic apparatus, this would be reflected in the number or in the kinetic parameters of the spikes or "foot" signals.
To avoid any effect derived from blockade of pregabalin on VDCC, cells were permeabilized with digitonin in a 10 µM free Ca 2+ solution to allow Ca 2+ entry into the cytosol. Original recordings of the spikes obtained under control conditions, and after incubation with 30 µM pregabalin for 1 h are shown in Fig. 5A and B, respectively. Typical spikes recorded under both conditions (marked with an asterisk) are displayed at the right of the panels.
The average number of "foot" signals obtained in control and pregabalin-treated cells was similar (Table 1 ). The following parameters were determined for each "foot" signal: Imax (maximal amplitude), t (duration), Q (charge, expressed as pC or as number of molecules) and n foot (number of "foot" signals). The parameters of the amperometric "foot" signals of the spikes obtained in the digitonin-treated cells were unchanged in the presence of pregabalin, as shown in Table 1 . This means that pregabalin does not act on the fusion pore formed between the secretory vesicle and the plasma membrane to release the neurotransmitter content stored at the chromaffin vesicle.
The average number of spikes obtained in control or pregabalin-treated cells was identical. The kinetic parameters of the individual amperometric spikes were not either modified after pregabalin treatment ( Table 2 ). The following parameters were determined: I max (peak amplitude), Q (charge), m (ascending slope, calculated from the linear portion of the trace between 25% and 75% of the I max ), t 1/2 (half-width or duration of the amperometric signal at 50% of its peak amplitude) and t p (time-to-peak, time from the start of the spike until the peak in seconds) (Fig. 6A ). In addition, the frequency histograms of the different parameters under both conditions did not vary after the (Fig. 6B ).
Positive control experiments of the negative effect of pregabalin on the exocytotic apparatus were performed using the anti-SNARE tetanus toxin. This toxin has been shown to inhibit exocytosis in chromaffin cells (Penner et al., 1986; Bittner and Holz, 1998; Xu et al., 1998) . Digitoninpermeabilized cells were incubated for 3 min with 300 nM tetanus toxin, resulting in a marked reduction of the number of amperometric spikes (227 spikes in control versus 96 spikes in tetanus toxin-treated cells, n= 6 cells, p=0.002) (Supplemental Figure 1) .
Pregabalin does not interfere with the mitochondrial Ca 2+ fluxes in mouse chromaffin cells
Pregabalin uses the system L of amino acid transport across the plasma membrane to generate its neuronal effects (Jezyk et al., 1999; Su et al., 2005) . Thus, pregabalin might enter the cell and interact with mitochondria, an organelle implied in epilepsy. Mitochondrial Ca 2+ transients were monitored using mit-r-Pericam. Digitonin-permeabilized cells were perfused with a solution containing 30 μ M Ca
2+
, to analize how mitochondria uptakes and releases Ca 2+ under control conditions (n=14 cells) and after 20 min pretreatment with pregabalin (n=15 cells) (Fig. 7) .
The following kinetic parameters of the mitochondrial Ca 2+ signal were determined: t peak (time-topeak, time from the start of the rise until the maximal value of the fluorescence ratio in seconds), increase (increment of the fluorescence ratio from the basal line to the maximal value), decrease at 150 s (decrement of the fluorescence ratio from the maximal value until 150 seconds later) and tau (time constant) (Fig. 7A ).
DISCUSSION
The mechanism of action of pregabalin to inhibit Ca 2+ channels and consequently neurotransmitter release has been reported to be mediated by the α 2δ-1 subunit of VDCC (Field et al., 2006; Quintero et al., 2011) . Other targets different to these auxiliary subunits have been posed (Cunnnigham et al., 2004; McClelland et al., 2004; Micheva et al., 2006) . Indeed, some intracellular additional mechanism might explain its inhibitory action on neurotransmitter release since pregabalin uses the system L of amino acid transport across the plasma membrane to enter into the cytosol (Su et al., 2005) . Therefore, it is plausible that pregabalin interacts with cellular structures such as the fusion pore, the exocytotic machinery or intracellular organelles such as the mitochondria, involved in the epileptogenic processes, to reduce neurotransmitter release.
In the present study, high-resolution techniques were used to investigate possible functional interactions of pregabalin with VDCC, fusion pore, exocytotic machinery and mitochondria. The main findings achieved in the present study are: i) pregabalin inhibited VDCC and exocytosis in mouse, human and bovine chromaffin cells of the adrenal gland, thus limiting the release of catecholamines to the bloodstream; ii) the inhibition of pregabalin on VDCC is partially mediated by α 2δ auxiliary subunits of Ca 2+ channels; iii) pregabalin inhibition of VDCC does not depend on α 1 Ca 2+ channel types; iv) pregabalin does not interfere with the fusion pore, the exocytotic machinery or the handling of Ca 2+ by mitochondria.
In relation to the inhibitory effect of pregabalin on VDCC, we first investigated whether it was mediated through α 2δ auxiliary subunits. Transcripts for α 2δ auxiliary subunits have been reported Di Guilmi et al., 2011) , shows that pregabalin acts through α 2δ-dependent and independent mechanisms to regulate Ca 2+ channels and neurotransmitter release.
Extensive research has been performed on the VDCC type targeted by gabapentin. This drug was found to preferentially inhibit Cav1 (Stefani et al., 2001 ), Cav2.1 (Bayer et al., 2004) and Cav2.2 (Sutton et al., 2002) channels. Pregabalin has been reported to inhibit Cav2.1 channels (Dooley et al., 2002; Fink et al., 2002; Di Guilmi et al., 2011) . In the present study we found that pregabalin inhibits Cav1, Cav2.1 and Cav2.2 channel types. However, Martin and coworkers (2001) On the other hand, the possibility that pregabalin may be acting on different targets to Ca 2+ channels have been previously proposed (Cunningham et al., 2004; McClelland et al., 2004; Micheva et al., 2006) . In the present study, the action of pregabalin on the fusion pore formed between the plasma membrane and the secretory vesicle, the exocytotic apparatus or the mitochondria were also evaluated. Indeed, the anticonvulsivant topiramate has been shown to affect the SNARE-associated monoamine exocytotic mechanism (Okada et al., 2005) . To investigate the action of pregabalin on the fusion pore and the exocytotic machinery, cells were treated with digitonin to avoid the effect of pregabalin on VDCC, so that Ca 2+ would access the cytosol through pores formed by the detergent in the plasma membrane. If the fusion pore or any protein of the exocytotic machinery would be affected by the drug, a significant change in the number or the kinetic parameters of "foot" signals or spikes, recorded with the carbon fibre amperometric technique in single cells would be detected.
However, this was not the case, reflecting that pregabalin does not act on these cellular structures.
It has been reported that mitochondria is largely involved in epilepsy (Folbergrová and Kunz, 2011 Our study reports the effect of pregabalin on VDCC of chromaffin cells of the adrenal gland, the main source of adrenaline released to the bloodstream, an effect that might have clinical consequences. Indeed, it has been reported that pregabalin treatment improved heart rate variability ). An increased resting heart rate is frequently observed in diabetic patients, most likely due to vagal cardiac neuropathy that results in increased cardiac sympathetic activity. The tachycardia may be followed by a decrease in heart rate and, ultimately, by a fixed heart rate due to progressive dysfunction of the cardiac sympathetic nervous system. Therefore, pregabalin, by decreasing the exocytotic process, and consequently the adrenaline release, would initially diminish reflex taquicardia, thus estabilizing heart rate.
On the other hand, a decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain has been observed, probably due not only to the effect of pregabalin on VDCC of myopathic ventricles (Murphy et al., 2007) , but also, as shown in the present study, to the decrease of the exocytotic process, and consequently of adrenaline release, yielded by the drug in human chromaffin cells.
In conclusion, our data show that pregabalin inhibits exocytosis by blocking Cav1, Cav2.1 and Cav2.2 channels through α 2δ-dependent and independent pathways. These mechanisms lead to the inhibition of Ca 2+ channels to a certain extent, independently of the amount and type of α 1 Ca 2+ channel types. The inhibition of Ca 2+ channels by pregabalin provokes the inhibition of the exocytotic process, which might possess clinical relevance. Finally, pregabalin does not act on other targets related with exocytosis or Ca 2+ homeostasia such as the fusion pore, the exocytotic machinery and the mitochondria. This selective mechanism of action of the drug may contribute to its safety, good tolerability and lack of adverse effects.
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